פרופ׳ שומרון בן-חורין
  מומחה לגסטרואנטרולוגיה
(מחלות מערכת העיכול ואנדוסקופיות)
מנהל מכון הגסטרואנטרולוגי ומנהל המעבדה הגסטרו-אימונולוגית שיבא, תל השומר

Ben-Horin S *, Novack L*, Guo J, Zhao Y, Mao R, Sergienko  R, Zhang J, Kobayashi T, Hibi T, Chowers  Y, Peyrin-Biroulet L, Colombel JF, Kaplan GG, Chen MH.

Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: A systematic review and an individual-patient level meta-analysis of randomized controlled trials. Gastroenterology 2022

 

Ben-Horin S, Har-Noy O, Katsanos KH, Roblin X, Chen M, Gao X, Schwartz D, Cheon JH, Cesarini M, Bojic D, Protic M, Theodoropoulou A, Abu-Kaf H, Engel T, Tang J, Veyrard P, Lin X, Mao R, Christodoulou D, Karmiris K, Knezevic-Ivanovski T; ComboMesa investigators. Corticosteroids and 5-ASA versus corticosteroids for acute severe ulcerative colitis: A randomized controlled trial. Clin Gastroenterol Hepatol. 2022 

 

Ungar B, Malickova K, Hanžel J, Abu-Arisha M, Paul S, Rocha C, Ben-Shatach Z, Abitbol CM, Haj-Natour O, Selinger L, Yavzori M, Fudim E, Picard O, Shoval I, Eliakim R, Kopylov U, Magro F, Roblin X, Chowers Y, Drobne D, Lukas M, Ben-Horin S.                   

Dose-optimization for loss-of-response to vedolizumab: pharmacokinetics and immune mechanisms. J Crohns Colitis. 2021  

 

Schreiber S*, Ben-Horin S* Leszczyszyn J, Dudkowiak R, Lahat A, Gawdis-Wojnarska B, Pukitis A, Horynski M, Farkas K, Kierkus J, Kowalski M, Lee SJ, Kim SH, Suh JH, Kim MR, Lee SG, Ye BD, Reinisch W.    

Randomized Controlled Trial: Subcutaneous versus Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. Gastroenterology 2021

​

Klang E, Kopylov U, Mortensen B, Damholt A, Soffer S, Barash Y, Konen E, Grinman A, Yehuda RM, Buckley M, Shanahan F, Eliakim R, Ben-Horin S.

A Convolutional Neural Network Deep Learning Model Trained on CD Ulcers Images Accurately Identifies NSAID Ulcers. Front Med 2021

​

Ben-Horin S, Lahat A, Amitai MM, Klang E, Yablecovitch D, Neuman S, Levhar N, Selinger L, Rozendorn N, Turner D, Chowers Y, Odes S, Schwartz D, Yanai H,  Dotan I ,Braun T, Haberman Y, Kopylov U,  Eliakim Rami. Assessment of small bowel mucosal healing by video capsule endoscopy predicts short and long-term risk of Crohn’s disease flare: A prospective cohort study. Lancet Gastroenterol Hepatol 2019

 

Ungar B, Kopylov U, Yavzori M, Fudim E, Picard O, Lahat A, Coscas D, Waterman M, Haj-Natour O, Orbach-Zingboim N, Mao R, Chen M, Chowers Y, Eliakim R, Ben-Horin S. Association of Vedolizumab Level, Anti-Drug Antibodies, and alpha4beta7 Occupancy With Response in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2018 

 

Ungar B, Engel T, Yablecovitch D, Lahat A, Lang A, Avidan B, Har-Noy O, Carter D, Levhar N, Selinger L, Neuman S, Natour OH, Yavzori M, Fudim E, Picard O, Kopylov U, Chowers Y, Naftali T, Broide E, Shachar E, Eliakim R, Ben-Horin S. Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and Drug Concentrations: The POETIC Study. Am J Gastroenterol. 2018 

 

Ben-Horin S, Ungar B, Kopylov U, Lahat A, Yavzori M, Fudim E, Picard O, Peled Y, Eliakim R, Del Tedesco E, Paul S, Roblin X.          Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.  Aliment Pharmacol Ther. 2018

 

Ben-Horin S, Andrews JM, Katsanos KH, Rieder F, Steinwurz F, Karmiris K, Cheon JH, Moran GW, Cesarini M, Stone CD, Schwartz D, Protic M, Roblin X, Roda G, Chen MH, Har-Noy O, Bernstein CN. Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: A global survey of physicians' practice. World J Gastroenterol. 2017

​

Ungar B, Yoav Mazor, Roni Weisshof, Henit Yanai, Idan Goren, Amir Waizbard, Miri Yavzori, Ella Fudim, Orit Picard, Ronen Loebstein, Uri Kopylov, Iris Dotan, Yehuda Chowers, Rami Eliakim, Ben-Horin S. Induction infliximab levels among patients with acute severe ulcerative colitis compared to patients with moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2016

​

Ben-Horin S, Yavzori M, Benhar I, Picard O, Fudim E, Ungar B, Lee SY, Kim SH, Eliakim R, Chowers Y. Cross-immunogenicity: Antibodies to infliximab in Remicade-treated IBD patients similarly recognize the bio-similar Remsima.  Gut 2016

​

Ben-Horin S, Vande Casteele N, Schreiber S, Lakatos PL. Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation. Clin Gastroenterol Hepatol 2016 (Review) 

​

Ben-Horin S, Itzhaki Z, Haj-Natour O, Segev S, Eliakim R, Avidan B.   Rarity of Adenomatous polyps in ulcerative colitis: Implications for colonic carcinogensis.   Endoscopy 2016

​

Ben-Horin S. Drug Level-based Anti-Tumor Necrosis Factor Therapy: Ready for Prime Time?. Gastroenterology 2015 (Editorial)

​

Kopylov U, Yablecovitch D, Lahat A, Neuman S, Levhar N, Greener T, Klang E, Rozendorn N, Amitai MM, Ben-Horin S*, Eliakim R*.  Detection of Small Bowel Mucosal Healing and Deep Remission in Patients With Known Small Bowel Crohn's Disease Using biomarkers, Capsule Endoscopy, and Imaging.   Am J Gastroenterol 2015

​

Ben-Horin S, Chowers Y, Ungar B, Kopylov U, Loebstein R, Weiss B, Eliakim R, Del Tedesco E, Paul S, Roblin X.   Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal. Aliment Pharmacol Ther 2015

​

Lang A, Salomon N, Wu JC, Kopylov U, Lahat A, Har-Noy O, Ching JY, Cheong PK, Avidan B, Gamus D, Kaimakliotis I, Eliakim R, Ng SC, Ben-Horin S.   Curcumin in Combination With 5-aminosalycilate Induces Remission in Patients with Mild to Moderate Ulcerative Colitis in a Randomized Controlled Trial. Clin Gastroenterol Hepatol 2015

​

Yanai H, Lichtenstein L, Assa A, Mazor Y, Weiss B, Levine A, Ron Y, Kopylov U, Bujanover Y, Rosenbach Y, Ungar B, Eliakim R, Chowers Y, Shamir R, Fraser G, Dotan I, Ben-Horin S.  Levels of Drug and Anti-drug Antibodies are Associated with Outcome of Interventions after Loss of Response to Infliximab or Adalimumab. Clin Gastroenterol Heaptol 2015

​

Ben-Horin S, Heap GA, Ahmad T, Kim H, Kwon T, Chowers Y. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications? Expert Rev Gastroenterol Hepatol 2015 (Review)

​

Ungar B, Chowers Y, Yavzori M, Picard O, Fudim E, Har-Noy O, Kopylov U, Elyakim R, Ben-Horin S.  The temporal evolution of anti-drug antibodies in inflammatory bowel disease patients treated with infliximab. Gut 2014

​

Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol 2014 (Review)

​

Ben-Horin S, Waterman M, Kopylov U, Yavzori M, Picard O, Fudim E, Awadie A, Weiss B, Chowers Y.  Elimination of detectable anti-infliximab antibodies and reversal of loss of response by the addition of an immuno-modulator.  Clin Gastroenterol Hepatol 2013

​

Ben-Horin S, Polak-Charcon S, Barshack I, Picard O, Fudim E, Yavzori M, Avivi C, Mardoukh C, Shimoni A, Chowers Y, Maor Y.  Celiac disease resolution after allogeneic bone marrow transplantation is associated with absence of Gliadin-specific memory response by donor-derived intestinal T-cells.    J Clin Immunol 2013

​

Ben-Horin S, Bujanover Y, Goldstein S, Nadler M, Lang A, Kopylov U, Katz L, Schwartz E, Avidan B .    Travel associated health risks for patients with inflammatory bowel disease.    Clin Gastroenterol Hepatol 2012

​

Ben-Horin S, Mazor Y, Yanai H, Ron Y, Kopylov U, Yavzori M, Picard O, Fudim E, Maor Y, Lahat A, Coscas D, Eliakim R, Dotan I, Chowers Y.   The decline of anti-drug antibody titers after discontinuation of anti-TNFs:  Implications for predicting re-induction outcome in IBD. Aliment Pharmacol Ther 2012

​

Katz L, Gisbert JP, Manoogian B, Lin K, Steenholdt  C, Atreja A, Ron Y, Swaminath A, Mantzaris GJ, Shah S, Hart A, Lakatos PL, Ellul P, Israeli E, Svendsen  MS, van der Woude  CJ, Katsanos KH , Tsianos EV, Natha T, Abreu M, Dotan I, Lashner B, Brynkov J, Terdiman JP, Higgins PDR, Chaparro M, Ben-Horin S.  Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response   Inflamm Bowel Dis 2012

​

Yanai H, Nguyen GC, Yun L,  Lebwohl O, Navaneethan U, Stone CD, Ghazi L, Moayyedi P, Brooks J, Bernstein CN, Ben-Horin S.  The practice of gastroenterologists in treating flaring IBD patients with C.difficile: Antibiotics alone or combined antibiotics-Immunomodulators ?   Inflamm Bowel Dis 2011

​

Ben-Horin S, Yavzori M, Kopylov U, Picard O, Fudim E, Eliakim R, Chowers Y, Lang A.  Detection of Infliximab in breast milk of nursing mothers with inflammatory bowel disease.  J Crohn & Colitis 2011

​

Kopylov U,  Mantzaris GJ, Katsanos KH, Reenaers C, Ellul P, Rahier JF, Israeli E, Lakatos P, Fiorino G, Cesarini M, Tsianos E, Louis E, Ben-Horin S.   The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of Infliximab – A multi-center European study. Aliment Pharmacol Ther 2011

​

Ben-Horin S, Yavzori M, Katz L, Kopylov U, Picard O, Fudim e, Coscas D, Goldstein I, Chowers Y.  The immunogenic part of infliximab is the F(ab')2 fragment, but measuring antibodies to the intact infliximab molecule is more clinically useful.  Gut 2011

​

Ben-Horin S, Margalit M, Bossuyt P, Maul J, Shapira Y, Bojic D, Chermesh I, Al-Rifai A, Schoepfer A, Bosani M, Allez M, Lakatos PL, Bossa F, Eser A, Stefanelli T, Carbonnel F, Katsanos K, Checchin D, Sáenz de Miera I, Chowers Y, Moran GW, for the European Crohn's and Colitis Organization (ECCO). The impact of concomitant treatment by immuno-modulators and antibiotics on the outcome of C. difficile-associated inflammatory bowel disease exacerbation.  Clin Gastroenterol Hepatol 2009

​

Ben-Horin S, Goldstein I, Fudim E, Yerushalmi Z, Picard O , Barshack IC, Bank I, Goldschmid Y, Bar Meir S, Mayer L, Chowers Y. Thiopurines' delayed-onset of the anti-inflammatory effect: Early preservation of immune effector functions followed by eventual memory cell depletion.  Gut 2009

​

Ben-Horin S, Bar-Meir S, Avidan B.  The outcome of a second preparation for colonoscopy after preparation failure in the first procedure. Gastrointest Endosc 2009

​

Ben-Horin S, Bar-Meir S, Avidan B.  The impact of colon cleanliness assessment on endoscopists' recommendations for follow-up colonoscopy. Am J Gastroenterol 2007

​

Ben-Horin S, Green PHR, Bank I, Chess L, Goldstein I.   Characterizing the circulating Gliadin-specific CD4+ memory T-cells in patients with celiac disease: Linkage between memory function, gut homing and Th1 polarization.   J Leukoc Biol 2006

​

Ben-Horin S, Bardan E, Barshack I, Zaks N, Livneh A.  Cholesterol crystal embolization to the digestive system: characterization of a common, yet overlooked presentation of atheroembolism. Am J Gastroenterol 2003

​

Ben-Horin S, Farfel Z, Mouallem M.  Gastroenteritis-associated hyperamylasemia: Prevalence and clinical significance. Arch Intern Med 2002